Axonics Modulation Technologies disclosed positive top-line results from the ARTISAN-SNM pivotal study, designed to gain marketing approval from the U.S. FDA for the Axonics r-SNM System. The clinical study demonstrated that patients implanted with the Axonics r-SNM System received clinically meaningful and statistically significant improvements in Urinary Urgency Incontinence symptoms and quality of life. Additionally, the study met all secondary endpoints. No serious device-related adverse events have been reported.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.